Jul 13, 2026
Biogen (BIIB) Stock Jumps on Analyst Upgrade Before Key Alzheimer’s Data Release
Truist upgrades Biogen (BIIB) stock to Buy with $235 target ahead of Alzheimer's drug data. Shares rise 1.3% premarket on positive analyst outlook.
The post Biogen (BIIB) Stock Jumps on Analyst Upgrade Before Key Alzheimer’s Data Release appeared first on Blockonomi.
Source: Blockonomi →Related News
- 55 minutes ago
SK Hynix (SKHY) Stock Drops 5% Despite $38B Semiconductor Expansion Plan
- 1 hour ago
USA Rare Earth (USAR) Stock Surges 6% Before Q2 Results and SVRE Merger Decision
- 1 hour ago
Vistra (VST) Stock Dips as Q2 Revenue Falls Short by Nearly $2 Billion
- 1 hour ago
MP Materials (MP) Stock: Should You Buy After Q2 Beat and Major Defense Contract...
- 1 hour ago
Rocket Lab (RKLB) Stock Gains Momentum Following Major Space Force Contract Awar...